EQS-Adhoc: Fresenius SE & Co. KGaA: Fresenius SE & Co. KGaA confirms review of deconsolidation of Fresenius Medical Care through change of legal form into a stock corporation

As part of the „strategic review” initiated by Michael Sen, Chief Executive Officer of Fresenius SE & Co. KGaA (“the Issuer”), the Issuer is also analyzing the deconsolidation of its subsidiary Fresenius Medical Care AG & Co. KGaA (“FMC”), amongst other ways, through a change of the legal form into a stock corporation (Aktiengesellschaft). The Else Kröner-Fresenius-Stiftung which holds all shares in the Issuer’s general partner has informed the Issuer that it has taken note with approval of the Issuer’s plans to deconsolidate FMC by way of a change of the legal form into a stock corporation. The Issuer wishes to point out, however, that the analysis is not yet completed and the required decisions by the competent bodies within the group are still outstanding. Fresenius SE & Co. KGaA, represented by Fresenius Management SE, The Management Board  Bad Homburg v.d.H., February 9, 2023  Contact:Markus Georgi Senior Vice President Investor Relations & Sustainability T: +49 (0) 6172 608-2485 markus.georgi@fresenius.com End of Note